These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 23603165)

  • 1. Treatment optimization in MS: Canadian MS Working Group updated recommendations.
    Freedman MS; Selchen D; Arnold DL; Prat A; Banwell B; Yeung M; Morgenthau D; Lapierre Y;
    Can J Neurol Sci; 2013 May; 40(3):307-23. PubMed ID: 23603165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utility of the Canadian Treatment Optimization Recommendations (TOR) in MS care.
    Grand'Maison F; Bhan V; Freedman MS; Myles ML; Patry DG; Selchen DH; Moriarty P; Traboulsee AL
    Can J Neurol Sci; 2013 Jul; 40(4):527-35. PubMed ID: 23786735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of relapsing-remitting multiple sclerosis in Latin America: practical recommendations for treatment optimization.
    Correale J; Abad P; Alvarenga R; Alves-Leon S; Armas E; Barahona J; Buzó R; Corona T; Cristiano E; Gracia F; Bonitto JG; Macías MA; Soto A; Vizcarra D; Freedman MS
    J Neurol Sci; 2014 Apr; 339(1-2):196-206. PubMed ID: 24607335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment optimization in multiple sclerosis.
    Freedman MS; Patry DG; Grand'Maison F; Myles ML; Paty DW; Selchen DH;
    Can J Neurol Sci; 2004 May; 31(2):157-68. PubMed ID: 15198439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The toronto observational study of natalizumab in multiple sclerosis.
    Krysko KM; O'Connor PW
    Can J Neurol Sci; 2011 May; 38(3):422-8. PubMed ID: 21515500
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined MRI lesions and relapses as a surrogate for disability in multiple sclerosis.
    Sormani MP; Li DK; Bruzzi P; Stubinski B; Cornelisse P; Rocak S; De Stefano N
    Neurology; 2011 Nov; 77(18):1684-90. PubMed ID: 21975200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations.
    Freedman MS; Devonshire V; Duquette P; Giacomini PS; Giuliani F; Levin MC; Montalban X; Morrow SA; Oh J; Rotstein D; Yeh EA;
    Can J Neurol Sci; 2020 Jul; 47(4):437-455. PubMed ID: 32654681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
    Wingerchuk DM; Carter JL
    Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
    Kister I; Spelman T; Patti F; Duquette P; Trojano M; Izquierdo G; Lugaresi A; Grammond P; Sola P; Ferraro D; Grand'Maison F; Alroughani R; Terzi M; Boz C; Hupperts R; Lechner-Scott J; Kappos L; Pucci E; Hodgkinson S; Solaro C; Butzkueven H
    J Neurol Sci; 2018 Aug; 391():72-76. PubMed ID: 30103975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of diagnosis and early treatment on the course of multiple sclerosis.
    Noyes K; Weinstock-Guttman B
    Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial.
    Yadav V; Marracci G; Kim E; Spain R; Cameron M; Overs S; Riddehough A; Li DK; McDougall J; Lovera J; Murchison C; Bourdette D
    Mult Scler Relat Disord; 2016 Sep; 9():80-90. PubMed ID: 27645350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.
    Coyle PK; Khatri B; Edwards KR; Meca-Lallana JE; Cavalier S; Rufi P; Benamor M; Thangavelu K; Robinson M; Gold R;
    Mult Scler Relat Disord; 2018 Nov; 26():211-218. PubMed ID: 30273841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statin treatment in multiple sclerosis: a systematic review and meta-analysis.
    Pihl-Jensen G; Tsakiri A; Frederiksen JL
    CNS Drugs; 2015 Apr; 29(4):277-91. PubMed ID: 25795002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and MRI outcomes after stopping or switching disease-modifying therapy in stable MS patients: a case series report.
    Berkovich R
    Mult Scler Relat Disord; 2017 Oct; 17():123-127. PubMed ID: 29055441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of worsening multiple sclerosis with mitoxantrone: a review.
    Fox EJ
    Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.